Objective

To analyze the results of surveillance of adverse events of special interest (AESI) within the context of the COVID-19 vaccination campaign at a sentinel site in Argentina. The retrospective (pre-vaccination) period was compared with the prospective (vaccination) period to identify safety signals. 

Method

Retrospective and prospective search for AESI based on ICD-10 hospital discharge codes. A descriptive analysis, moving-averages trend smoothing, and control charts were used to detect changes in AESI behavior. 

Objective

To describe the implementation and pioneering work of a vaccine pharmacovigilance committee in the state of São Paulo, Brazil, for the analysis of events supposedly attributable to vaccination or immunization (ESAVI) during the COVID-19 pandemic.

The objective of this study was to analyze the role of risk communication in the response to cases of adverse events supposedly attributable to vaccination and immunization (ESAVI) in countries of the Americas.

Objective

To describe the comprehensive activities implemented in the Bolivarian Republic of Venezuela to achieve reverification of measles elimination by 2023. 

Method

Descriptive study of the procedures implemented to achieve reverification of measles elimination by 2023 according to the components set forth in the Regional Framework for the Monitoring and Re-verification of Measles, Rubella, and Congenital Rubella Syndrome Elimination in the Americas, published in 2022. 

Objective

To estimate the direct costs associated with the diagnosis, treatment, and control of measles cases in Brazil from 2018 to 2020.

Since the last case of indigenous rubella virus (RuV) was detected in 2009 in the Region of the Americas, sporadic rubella and congenital rubella cases have been confirmed, and subsequently, a low number of associated sequences have been reported. Fifty-one sequences of wild-type RuV, representing four genotypes (1E, 1G, 1J, and 2B), were reported from five countries, with confirmed sources of exposure for 46 cases. Phylogenetic analysis revealed the diversity of these viruses, showing no associations with sustained endemic transmission from previously endemic strains.

Objective

To describe Mexico’s experience of a high-quality follow-up vaccination campaign against measles and rubella in children aged 1 to 4 years, and actions taken to recover the coverage of other biologics during the COVID-19 health emergency. 

Method

Use of a microplanning tool in the design and implementation of a follow-up campaign to protect 8 604 781 girls and boys aged 1 to 4 years and to complete other vaccination schedules, followed by the implementation of rapid vaccination monitoring. 

Objective

To describe the impact of the new intervention model implemented by Paraguay across five districts of the Central Region in the last quarter of 2023, consisting of an integrated health services-based strategy to recover coverage with the tracer vaccine (pentavalent until April 2023, hexavalent thereafter) in children under 1 year of age; and the measles, mumps, and rubella (MMR) vaccine for the 1-year-old population. 

Objective

To describe the strategy implemented for interruption of the 2019-2020 measles outbreak in the Metropolitan Area of Buenos Aires (Argentina) and application of the Pan American Health Organization (PAHO) standardized outbreak closure criteria to verify interruption of viral circulation in an adverse setting (the COVID-19 pandemic). 

The elimination of endemic rubella and measles transmission in the Region of the Americas was verified by the Pan American Health Organization’s (PAHO) Regional Verification Commission in 2015 and 2016, respectively. Upon achieving this success, this Commission was disbanded. Shortly afterwards, the Region faced challenges in the post-elimination era, notably responding to and stopping transmission of imported measles cases. As a result, Brazil and Venezuela (Bolivarian Republic of) lost their measles-free status in February 2019 and July 2018, respectively.